泽布替尼治疗复发或难治性套细胞淋巴瘤
该1/2期研究评估了泽布替尼在复发/难治性套细胞淋巴瘤患者中的疗效与安全性,总日剂量320 mg组(N=32)中位随访18.8个月,总缓解率84%,完全缓解率25%,中位缓解持续时间18.5个月,中位无进展生存期21.1个月,耐受性良好。
要点
- 泽布替尼320 mg总日剂量在R/R MCL中总缓解率达84%,完全缓解率25%。
- 中位无进展生存期21.1个月,中位缓解持续时间18.5个月。
- ≥3级不良事件发生率59.4%,≥3级感染发生率18.8%。
核心结论
- 泽布替尼在复发/难治性套细胞淋巴瘤患者中耐受性良好并显示出抗肿瘤活性。
研究设计与样本
- 1/2期研究,纳入复发/难治性套细胞淋巴瘤患者,接受泽布替尼总日剂量320 mg(N=32),中位随访18.8个月。
主要发现
- 总缓解率84%,完全缓解率25%,中位缓解持续时间18.5个月,中位无进展生存期21.1个月。
- 18例患者终止治疗,其中10例因疾病进展,8例因不良事件。
- 最常见不良事件为腹泻(43.8%)、瘀伤(37.5%)、便秘(31.3%)和上呼吸道感染(31.3%)。
- 18.8%的患者发生≥3级感染;59.4%的患者报告至少1件≥3级不良事件。
- 发生率>2例的≥3级不良事件包括贫血(12.5%)、肺炎(9.4%)和肌痛(9.4%)。
关键数值与推荐
- 泽布替尼给药方案为160 mg每日两次(n=14)或320 mg每日一次(n=18),总日剂量320 mg组共32例。
临床怎么用
- 泽布替尼320 mg总日剂量可作为复发/难治性套细胞淋巴瘤的治疗选择,需关注感染等不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Zanubrutinib, a highly selective Bruton tyrosine kinase inhibitor, was evaluated in a phase 1/2 study in patients with various B-cell malignancies. In the subgroup of patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), zanubrutinib was administered as 160 mg twice daily (n = 14), 320 mg once daily (n = 18), or ≤160 mg total dose (n = 5). Herein, we report results for patients receiving a total daily dose of 320 mg (N = 32). Median study follow-up was 18.8 months. Eighteen patients discontinued treatment, 10 because of progressive disease and 8 because of adverse events (AEs); 1 AE (peripheral edema) was considered to be related to zanubrutinib treatment. The most common AEs were diarrhea (43.8%), contusion (37.5%), constipation (31.3%), and upper respiratory tract infection (31.3%). Infection was the most commonly reported AE of interest (18.8% of patients experienced grade ≥3 infection). At least 1 AE of grade ≥3 was reported in 59.4% of patients; grade ≥3 AEs that were reported in >2 patients were anemia (12.5%), pneumonia (9.4%), and myalgia (9.4%). Overall response rate was 84%, with 25% achieving a complete response. Median duration of response was 18.5 months. Median progression-free survival (PFS) was 21.1 months. Zanubrutinib was well tolerated and demonstrated activity in patients with R/R MCL. The trial is registered at www.clinicaltrials.gov as #NCT02343120.
引用
- Tam CS, Opat S, Simpson D, et al. Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv. 2021. PMID: 34152395. doi:10.1182/bloodadvances.2020004074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。